News
CDMO
7.35
+0.41%
0.03
Craig-Hallum Remains a Buy on Avid Bioservices (CDMO)
TipRanks · 1d ago
Avid Bioservices Q3 Financial Results Conference Call Announcement
TipRanks · 1d ago
Avid Bioservices misses top-line and bottom-line estimates; reaffirms FY24 outlook
Avid Bioservices misses top-line and bottom-line estimates; reaffirms FY24 outlook. The company has signed $41 million in net new business, resulting in a record high backlog of $206 million. Avid maintains revenue guidance for full fiscal year 2024 of $137 million to $147 million.
Seeking Alpha · 1d ago
CDMO Stock Earnings: Avid Bioservices Misses EPS, Beats Revenue for Q3 2024
Avid Bioservices reported earnings per share of -8 cents for the third quarter of 2024. The company reported revenue of $33.82 million. This was 1.09% better than the analyst estimate for the same period. Avid B bioservices also reported results for the second quarter.
Investorplace · 1d ago
Avid Bioservices Q3 2024 GAAP EPS $(0.09) Misses $(0.05) Estimate, Sales $33.800M Beat $33.452M Estimate
Avid Bioservices reported quarterly losses of $0.09 per share. The company reported quarterly sales of $33.800 million. This is a 11.09 percent decrease over sales of the same period last year. Avid missed the analyst consensus estimate by 80 percent.
Benzinga · 2d ago
Avid Bioservices Inc reports results for the quarter ended in January - Earnings Summary
Avid Bioservices Inc reports results for the quarter ended in January. The company reported a quarterly adjusted loss of 9 cents per share. Revenue fell 11.1% to $33.82 million from a year ago. The average analyst rating on the company's shares is "buy"
Reuters · 2d ago
*Avid Bioservices Backs FY24 Rev $137M-$147M >CDMO
Dow Jones · 2d ago
AVID BIOSERVICES OUTLOOK FY REVENUE USD 137-147 MILLION
Reuters · 2d ago
AVID BIOSERVICES INC - QTRLY SHR LOSS $ 0.09
Reuters · 2d ago
AVID BIOSERVICES REPORTS FINANCIAL RESULTS FOR THIRD QUARTER ENDED JANUARY 31, 2024
Reuters · 2d ago
*Avid Bioservices 3Q Loss/Shr 9c >CDMO
Dow Jones · 2d ago
Press Release: Avid Bioservices Reports Financial -2-
Avid signed multiple new orders totaling $41 million in the third quarter of fiscal 2024. The company has a record high revenue backlog of $206 million. Avid will host a webcast on April 29, 2024, at 4:30 p.m. The company is a dedicated development and manufacturing company.
Dow Jones · 2d ago
Press Release: Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
Avid Bioservices reports financial results for the third quarter and nine months ended January 31, 2024. Recorded third quarter revenue of $33.8 million and a record high backlog of $206 million. Company recently completed grand opening of cell and gene therapy manufacturing facility in January 2024. Avid is a dedicated biologics contract development and manufacturing organization.
Dow Jones · 2d ago
Weekly Report: what happened at CDMO last week (0415-0419)?
Weekly Report · 4d ago
Laughing Water Capital - Avid Bioservices: A Few Years Away From Large, Relatively Sticky FCF
Avid Bioservices recently experienced one of the worst "own goals" in public markets. Despite this, the long-term thesis is very much intact. Avid is still on their way to filling up their $400M in revenue capacity. With shares presently around $7, I think there is plenty of upside left.
Seeking Alpha · 5d ago
Laughing Water Capital Q1 2024 Letter
Seeking Alpha · 04/18 16:40
UPDATE 1-EnQuest selling stake in North Sea Golden Eagle oilfield, sources say
EnQuest selling stake in North Sea Golden Eagle oilfield, sources say. Britain's EnQuest is looking to sell its 27% stake in the Golden Eagle field in the British North Sea. The company bought the stake from Suncor in 2021 for $325 million. EnQuest has struggled in recent years with high debt levels.
Reuters · 04/16 14:42
Analysts’ Top Healthcare Picks: Avid Bioservices (CDMO), LifeMD (LFMD)
TipRanks · 04/16 12:40
Weekly Report: what happened at CDMO last week (0408-0412)?
Weekly Report · 04/15 09:40
More
Webull provides a variety of real-time CDMO stock news. You can receive the latest news about Avid Bioservices through multiple platforms. This information may help you make smarter investment decisions.
About CDMO
Avid Bioservices, Inc. is a contract development and manufacturing organization (CDMO). The Company provides a range of services from process development to Current Good Manufacturing Practices (CGMP) clinical and commercial manufacturing of biologics for the biotechnology and biopharmaceutical industries. It operates in a single segment, which is contract manufacturing and development services. The Company’s services include clinical and commercial product manufacturing, bulk packaging, release and stability testing and regulatory submissions support. The Company also provides a variety of process development services, including upstream and downstream development and optimization, analytical methods development, testing and characterization. It provides fully integrated and customized biomanufacturing services that support its customers from the early preclinical stage to commercial launch and supply.